WF-10 is under clinical development by Crescita Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect WF-10’s likelihood of approval (LoA) and phase transition for Diabetic Foot Ulcers took place on 23 Oct 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their WF-10 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

WF-10 overview

WF-10 is under development for the treatment of diabetic foot ulcer. It was under development for the treatment of persistent allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis and rheumatoid arthritis. It is administered as intravenous infusion. WF10 is a solution of OXO-K993 containing stabilized chlorite ions.

Crescita Therapeutics overview

Crescita Therapeutics operates as a commercial dermatology company that offers prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. The company’s products comprise Pliaglis, Alyria, Laboratoire Dr Renaud, Pro-Derm, Premiology, and ISDIN. Its Pliaglis is a local anesthetic cream for superficial dermatological and cosmetic procedures. Crescita Therapeutics develops Mical used in therapeutic areas of psoriasis and dermatological skin treatment. The company develops products using drug delivery platforms which include multiplexed molecular penetration enhancers and DuraPeel. It markets products throughout the US, Canada and Mexico. Crescita Therapeutics is headquartered in Laval, Ontario, Canada.

Quick View WF-10 LOA Data

Report Segments
  • Innovator
Drug Name
  • WF-10
Administration Pathway
  • Intravenous
  • Parenteral
Therapeutic Areas
  • Immunology
  • Metabolic Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.